Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
In a double-blind, placebo-controlled, U.S. Phase III trial in about 38,500 patients aged 60 or older, Zostavax met the primary endpoint. The overall BOI score, a measure of the average severity, inci...
